Димитриос Карусис

Научные публикации

• Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis
• Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
• Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint
• Application of diagnostic criteria for optic neuritis - Authors' reply
• Diagnosis and classification of optic neuritis
• A case report of unilateral cervical lymphadenopathy and multiple cranial neuropathies following mRNA-COVID-19 vaccination
• Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES
• Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis
• Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses
• Anatomical and functional visual network patterns in progressive multiple sclerosis
• A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis
• Beneficial effects of a nano formulation of pomegranate seed oil, GranaGard, on the cognitive function of multiple sclerosis patients
• Long-Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cell Injections in Patients With Progressive Forms of Multiple Sclerosis
• Synergistic neuroprotective effects of Fingolimod and mesenchymal stem cells (MSC) in experimental autoimmune encephalomyelitis
• Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis
• Conduction delays in the visual pathways of progressive multiple sclerosis patients covary with brain structure
• Cerebrospinal Fluid (CSF) Exchange Therapy with Artificial CSF Enriched with Mesenchymal Stem Cell Secretions Ameliorates Cognitive Deficits and Brain Pathology in Alzheimer's Disease Mice
• Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT
• MULTIPLE SCLEROSIS THERAPY - 2019
• Neuralized mesenchymal stem cells (NMSC) exhibit phenotypical, and biological evidence of neuronal transdifferentiation and suppress EAE more effectively than unmodified MSC
• Vision and Vision-Related Measures in Progressive Multiple Sclerosis
• The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy
• Cerebrospinal Fluid (CSF) Exchange with Artificial CSF Enriched with Mesenchymal Stem Cell Secretions Ameliorates Experimental Autoimmune Encephalomyelitis
• Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale
• NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness
• Development of a Novel Backbone Cyclic Peptide Inhibitor of the Innate Immune TLR/IL1R Signaling Protein MyD88
• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
• Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
• Cell-based therapeutic strategies for multiple sclerosis
• Sodium intake and multiple sclerosis activity and progression in BENEFIT
• Low-Density Lipoprotein Receptor-Related Protein 4-Positive Myasthenia Gravis in a Double-Seronegative, Electromyography-Negative Patient
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
• The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
• T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO)
• Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel
• Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials
• Sex-specific prediction of interferon beta therapy response in relapsing-remitting multiple sclerosis
• Tumefactive demyelination following in vitro fertilization (IVF)
• Delayed-onset flaccid paralysis related to west Nile virus reactivation following treatment with rituximab: a case report
• Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?
• NMO spectrum of disorders: a paradigm for astrocyte-targeting autoimmunity and its implications for MS and other CNS inflammatory diseases
• The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review
• The spectrum of post-vaccination inflammatory CNS demyelinating syndromes
• Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy
• Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
• Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors
• Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation
• Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1(G93A) mouse model
• Hematopoietic stem cell transplantation in multiple sclerosis
• Inflammation of the optic nerve: when it should be considered as neuromyelitis optica--the experience of the Department of Neurology at Hadassah Hospital